The invention relates to novel (1:1) salts of sorafenib and the hydrate and solvate forms thereof. More specifically the invention concerns: - the sorafenib hydrogen-bromide (1:1) monoacetonitrile solvate salt, - the sorafenib hydrogen-bromide (1:1) hemihydrate salt, - the sorafenib naphthalene-2-sulfonic acid (1:1) anhydrous (form I, II and III) salt, - the sorafenib naphthalene-2-sulfonic acid (1:1) monoethanol solvate salt. Moreover the invention relates to preparing the mentioned sorafenib salts, pharmaceutical compositions comprising them for the treatment of carcinoma.